+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06629363

Exploring Causes and Organ Damage in Malignant Hypertension Through the HAMA Biobank Study

Led by Centre Hospitalier de PAU · Updated on 2026-10-22

1000

Participants Needed

11

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are gathering and storing biological samples from patients with malignant hypertension, a severe and sudden form of high blood pressure that can quickly damage organs and be fatal if untreated. This observational study collects samples to better understand the diseases causes, identify new markers, and find potential treatment targets. The study includes patients from the HAMA cohort and covers various disease types. Samples are collected at two points newly diagnosed patients provide samples during the acute phase within 7 days of admission and again during a follow-up visit between 1 and 6 months. Pre-existing patients in the cohort may have a one-time genetic sample collected. Samples include serum, plasma, urine, blood DNA, and blood RNA, all stored under quality conditions. Participants undergo clinical and biological evaluations at diagnosis and during follow-up visits scheduled at 1, 3, 6, and 12 months, then annually for five years. Researchers monitor disease mechanisms, organ damage, and immune system involvement by linking sample analysis with patient data. This long-term follow-up helps decipher malignant hypertension progression and target organ damage development.

CONDITIONS

Brief Title

Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank

Research Team

A

Alice SERIS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here